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Abstract
Introduction: Autoantibodies to Ro52 recently identified as TRIM21 are among the most common autoantibodies
in systemic autoimmune rheumatic diseases, but their clinical association remains poorly understood. We
undertook this study to determine the clinical and serologic associations of anti-Ro52/TRIM21 antibodies in patients
with systemic sclerosis (SSc).
Methods: Detailed clinical data and sera from 963 patients with SSc enrolled in a multicenter cohort study were
collected and entered into a central database. Antibodies to Ro52/TRIM21 and other autoantibodies were detected
with an addressable laser-bead immunoassay and different enzyme-linked immunosorbent assay (ELISA) systems.
Associations between anti-Ro52/TRIM21 antibodies and clinical and other serologic manifestations of SSc were
investigated.
Results: Anti-Ro52/TRIM21 antibodies were present in 20% of SSc patients and overlapped with other main SSc-
related antibodies, including anti-centromere (by immunofluorescence and centromere protein (CENP)-A and
CENP-B ELISA), anti-topoisomerase I, anti-RNA polymerase III, and anti-Pm/Scl antibodies. Anti-Ro52/TRIM21
antibodies were strongly associated with interstitial lung disease (odds ratio (OR), 1.53; 95% confidence interval (CI),
1.11 to 2.12; P = 0.0091) and overlap syndrome (OR, 2.06; 95% CI, 1.01 to 4.19; P = 0.0059).
Conclusions: Anti-Ro52/TRIM21 antibodies were the second most common autoantibodies in this SSc cohort. In
SSc, anti-Ro52/TRIM21 antibodies may be a marker of interstitial lung disease and overlap syndrome.
Introduction
Systemic sclerosis (SSc; scleroderma) is a disorder char-
acterized by fibrosis of the skin and visceral organs. The
pathogenesis of this disease is complex and remains
incompletely understood. Nevertheless, autoantibodies
represent a serologic hallmark of the disease and have
proven value as diagnostic and prognostic biomarkers.
Indeed, up to 95% of SSc patients [1] have circulating
autoantibodies directed against one or more autoanti-
gens, including topoisomerase I (formerly called Scl-70),
centromere proteins (CENPs), RNA polymerase III, and
the PM/Scl complex, also known as the human exosome
[2]. In SSc, the major disease-related autoantibodies
tend to be mutually exclusive [3], suggesting unique
pathways for the induction of the B-cell response in this
condition. Evidence supporting this concept is extensive,
given data indicating that each autoantibody is asso-
ciated with specific demographic, clinical, genetic, and
prognostic features [4,5]. In addition, a growing knowl-
edge of the role of SSc autoantibodies in the pathogen-
esis of the disease is helping to gain a better
understanding of potential novel modes of therapy [6-9].
Two main types of SS-A/Ro antibodies have been
described in SSc. One is directed at a 60-kDa protein
known as SS-A/Ro60, which is part of a small cytoplas-
mic ribonucleoprotein (scRNP) multiprotein complex.
Another, which often coexists with the former SS-A/
Ro60 antibodies, is directed against a 52-kDa (Ro52)
protein that is not normally part of the scRNP complex
but is an E3 ubiquity ligase and a member of the tripar-
tite motif (TRIM) family of proteins known as TRIM21
[10]; hence, the preferred terminology of Ro52/TRIM21
is used in this report. The association of Ro60 antibo-
dies with autoimmune conditions is well established,
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particularly in systemic lupus erythematosus (SLE), sub-
acute cutaneous lupus, and Sjögren syndrome (SjS).
Ro52/TRIM21 antibodies have also been reported in a
wide variety of autoimmune diseases, although often
overlapping with other autoantibodies. However, little is
known of their clinical associations, and controversy still
exists about whether they have an independent associa-
tion with autoimmune diseases [11].
The Canadian Scleroderma Research Group (CSRG) is
a pan-Canadian, multicenter group of researchers that
has, since 2004, recruited more than 1,200 SSc patients.
The exact prevalence of SSc in Canada remains
unknown, but estimates range from 70 to 440 cases/mil-
lion [12,13]. Thus, by using the most conservative num-
bers, the CSRG currently captures up to 8% of all
Canadian SSc cases. Detailed demographic, clinical, and
serologic data have been obtained on these patients and
entered into a central database.
Ro52/TRIM21 antibodies have been identified in 20%
of the CSRG cohort, making it the second most common
autoantibody in this cohort of SSc patients (Table 1).
Given its high prevalence and the paucity of data on its
clinical significance, we undertook this study to deter-
mine whether Ro52/TRIM21 antibodies in SSc are asso-
ciated with distinct disease manifestations in SSc.
Methods
Design
This is a cross-sectional study of a cohort of SSc patients.
Study subjects
The study subjects consisted of those enrolled in the
Canadian Scleroderma Research Group (CSRG) registry.
Patients in this registry are recruited from the practices
of rheumatologists across Canada. They must have a
diagnosis of SSc confirmed by a rheumatologist, be 18
years of age or older, be fluent in English or French,
and be likely to be compliant with study procedures and
visits. The patients available for this study were those
whose baseline visit was between September 2004 and
February 2011.
Certain features of our cohort, including age, female
distribution, and proportion of patients with diffuse dis-
ease, suggest that the patients included in the CSRG
registry are similar to patients included in other large
SSc cohorts that have been assembled both in the Uni-
ted States and abroad [14]. Moreover, the cohort
includes a mix of patients covering the spectrum of dis-
ease severity. The participating rheumatologists in the
CSRG include both academic and community rheuma-
tologists, but all have a particular interest in SSc, and
thus all are perceived as “experts.” They thus recruit
patients with more severe disease. Conversely, because
the American College of Rheumatology classification cri-
teria for SSc exclude many patients with limited cuta-
neous disease [15,16], the patients in the CSRG Registry
do not have to meet those criteria to be included. Thus,
participating rheumatologists also recruit patients with
probably milder disease. Finally, the patients in the
CSRG Registry are generally recruited as outpatients,
and the mean disease duration is approximately 10
years. The cohort probably includes survivor patients
with less aggressive disease, but who may have accumu-
lated damage over time. In general, we believe that our
patients are representative of the spectrum of SSc seen
by the general rheumatology community in Canada.
Measurement of autoantibodies
Serum was collected from all patients recruited by the
CSRG and sent to a central laboratory, Mitogen
Advanced Diagnostics Laboratory, at the University of
Calgary. Aliquots of sera were stored at -70°C until
needed. Anti-Ro52/TRIM21 and other related autoanti-
bodies (topoisomerase I, chromatin, Sm, U1-RNP, ribo-
somal P, Jo-1, SSA/Ro60, SSB-La) were assayed with an
addressable laser-bead immunoassay (ALBIA) by using a
commercially available kit (QUANTAPlex ENA 8;
INOVA Diagnostics Inc., San Diego, CA, USA) in a
Luminex 100 (Luminex Corp., Austin, TX, USA) plat-
form, according to protocols previously described [17].
In addition, anti-CENP antibodies were assessed with
indirect immunofluorescence on an HEp-2000 substrate
(ImmunoConcepts Inc., Sacramento, CA, USA), and
antibodies to RNA polymerase III were detected with
ELISA (INOVA Diagnostics) [17], as were antibodies to
PM/Scl (PM1 alpha; Dr. Fooke Laboratorien GmbH,
Neuss, Germany) [18]. CENP-B ELISA (recombinant
full-length CENP-B), and CENP-A ELISA (Dr. Fooke




CENP-B 285 36% 162
Centromere by IIF 334 35% 2
CENP-A 275 34% 162
Ro52/TRIM21 194 20% 0
RNA polymerase III 144 19% 188
Topoisomerase I 150 16% 0
PM/Scl 53 7% 188
Ro60 53 6% 0
U1 RNP 59 6% 0
Chromatin 44 5% 0
Sm 39 4% 0
SS-B/La 26 3% 0
Jo-I 6 1% 0
Ribosomal P 14 1% 0
N = 963. CENP, centromere protein; IIF, indirect immunofluorescence; PM/Scl,
polymyositis/scleroderma (exosome) autoantigen; RNP, ribonucleoprotein; Sm,
Smith autoantigen; SS-B, Sjögren syndrome antigen B or La.
Hudson et al. Arthritis Research & Therapy 2012, 14:R50
http://arthritis-research.com/content/14/2/R50
Page 2 of 9
Laboratorien GmbH) were performed according to the
manufacturer’s AI-Line instructions for use, as pre-
viously described [19].
Study measures
Patients recruited into the Registry undergo an extensive
medical evaluation with standardized reporting of history,
physical evaluation, and laboratory investigations. Demo-
graphic information regarding age, sex, and ethnicity is
collected by patient self-report. Disease duration deter-
mined from the onset of the first non-Raynaud disease
manifestation is recorded by the study physician. Skin
involvement is assessed by using the modified Rodnan
skin score [20], a widely used clinical assessment in
which the examining rheumatologist records the degree
of skin thickening, ranging from 0 (no involvement) to 3
(severe thickening) in 17 areas (total score range, 0 to
51), and patients are classified into limited and diffuse
cutaneous subsets, based on the definition of Leroy et al.
[21]. Joint examinations are performed by a rheumatolo-
gist by using the simplified 28 swollen and tender joint
count [22]. History of inflammatory myositis, thrombosis,
scleroderma renal crisis, and overlap syndrome was
recorded by the study physician. For the purposes of this
study, overlap syndrome was defined as a patient with
SSc and SLE, SjS, rheumatoid arthritis, polymyositis/der-
matomyositis, and/or mixed connective tissue disease.
To assess gastrointestinal involvement, patients
answered yes/no to a series of 14 questions concerning
appetite loss, difficulty swallowing, regurgitation of acid,
nocturnal choking, heartburn, early satiety, abdominal
bloating, nausea and vomiting, constipation, diarrhea,
need for antibiotics for diarrhea, greasy stools, fecal
incontinence, and need for parenteral nutrition.
The presence of interstitial lung disease was deter-
mined by using a clinical decision rule that was recently
published [23]. This algorithm relies on physical exami-
nation (presence of typical “Velcro-like crackles” indica-
tive of interstitial lung disease on lung auscultation),
chest radiograph, and high-resolution computed tomo-
graphy (HRCT). Interstitial lung disease is considered
present if an HRCT lung study interpreted by an experi-
enced radiologist shows interstitial lung disease or, in
the case in which no HRCT was performed, if a chest
radiograph is reported as showing either increased inter-
stitial markings (not thought to be due to congestive
heart failure) or fibrosis, and/or if a study physician
reports the presence of typical Velcro-like crackles on
physical examination.
Systolic pulmonary artery pressure (SPAP) is mea-
sured by using the Doppler flow measurement of the tri-
cuspid regurgitant jet on echocardiography. Pulmonary
hypertension (PH) was defined as an estimated systolic
SPAP ≥ 45 mm Hg (an estimate that correlates strongly
with right-heart catheter studies [24]).
Disease severity is assessed by using physician and
patient global assessments of disease severity recorded on
a numeric rating scale ranging from 0, representing no dis-
ease, to 10, representing most-severe disease. Disease
severity also is measured by using a modified Medsger
Scleroderma Disease Severity Scale [25,26]. The scale
assesses disease severity in nine organ systems: general
health, peripheral vascular, skin, joint/tendon, muscle, gas-
trointestinal tract, lungs, heart, and kidneys. Each organ is
scored separately from 0 to 4, depending on whether no,
mild, moderate, severe, or end-stage involvement is pre-
sent. For the purposes of this study, the worst category
was scored for each system, and results of any investiga-
tion not requested by the physician, and therefore missing,
were considered “normal.” Scoring methods for general,
peripheral vascular, skin, joint/tendon, lung, and kidney
systems were identical to those proposed in the scale.
Some adaptations were made to the other organ systems.
To assign a score for the skeletal muscle system, physi-
cians were asked to rate patients’ muscle strength in five
different areas of the body (neck flexors, as well as upper
and lower proximal extremities, right and left) by using
the British Medical Research Council scale. A severity
score was then assigned depending on the total number of
5s, 4s, 3s, 2s, 1s, and 0s for a given patient. The HAQ-DI
was used to assess the patient’s use of ambulation aids
needed to assign the worst severity level for the skeletal
muscle system (that is, level 4, end stage).
To score the gastrointestinal system, in addition to an
abnormal esophagogram, abnormal esophageal manome-
try, or abnormal small-bowel series, patients reporting
difficulty swallowing, acid taste in their mouth, choking
at night, burning sensation, feeling of being full shortly
after eating, or taking gastroprotective or promotility
agents were also given a score of 1 for mild. In addition
to malabsorption syndrome and episodes of pseudo-
obstruction, patients with an abnormal hydrogen breath
test were given a score of 3 for severe.
To score the heart system, electrocardiogram results,
percentage left ventricular ejection fraction values, pre-
sence of conduction abnormalities, distended neck veins,
and arrhythmia diagnosed by a physician were used.
Statistical analysis
Descriptive statistics were used to summarize the base-
line characteristics of the patients. c2 tests, Yates c2
tests, Fisher Exact tests, and Mann-Whitney U tests
were used, as appropriate. P values < 0.05 were consid-
ered statistically significant. A sensitivity analysis was
performed in the subset of patients who met the 1980
American College of Rheumatology preliminary classifi-
cation criteria [27], of which 852 (89%) were found. All
of the results were similar. Thus, the results of the
whole cohort are presented here.
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All statistical analyses were performed with SAS v.9.2
(SAS Institute, San Diego, CA, USA).
Ethical considerations
Ethics committee approval for the CSRG data collection
protocol was obtained at McGill University (Montreal,
Ontario, Canada) and at all participating study sites. All
subjects provided informed written consent to partici-
pate in the data-collection protocol.
Results
This study included 963 SSc patients with complete ser-
ologic data on anti-Ro52/TRIM21 antibodies. Baseline
characteristics of the study cohort are presented in
Table 2. Mean age was 54.25 (± 12.04) years; 87% were
female; 85% were White; mean disease duration (since
the onset of the first non-Raynaud disease manifesta-
tion) was 11.04 (± 9.47) years; and 59% had limited, 37%
had diffuse, and 3% had no skin involvement.
Of the 963 SSc patients included in this study, 194 (20%)
were positive for anti-Ro52/TRIM21 antibodies. This
represents the second most common autoantibody in this
cohort with anti-centromere, anti-RNA polymerase III,
and anti-topoisomerase I antibodies present in approxi-
mately 35%, 19%, and 16% of the patients, respectively
(Table 1). Anti-Ro52/TRIM21 antibody-positive patients
were more likely to be older (57.16 versus 54.98 years; P =
0.0481), to have interstitial lung disease (44% versus 34%;
P = 0.0091), and to have overlap syndrome (22% versus
14%; P = 0.0059) compared with anti-Ro52/TRIM21 anti-
body-negative patients (Table 2). In particular, anti-Ro52/
TRIM21 antibody-positive patients were significantly
more likely to have overlap with polymyositis/dermato-
myositis (6% versus 3%; P = 0.0431) compared with anti-
Ro52/TRIM21 antibody-negative patients. Also of note,
two of 36 patients with polymyositis/dermatomyositis
overlap had anti-Jo-1 antibodies (6%), and both of these
had anti-Ro52/TRIM21 antibodies.
Disease severity measured by using the Medsger Dis-
ease Severity Scale was worse in two domains (range, 0
to 4): general (1.16 versus 0.82; P = 0.0061) and lung
(1.56 versus 1.34; P = 0.0084) in anti-Ro52/TRIM21
antibody-positive compared with anti-Ro52/TRIM21
antibody-negative patients (Table 3).









Odds ratio (95% CI) and
P values (Anti-Ro52/TRIM21
positive vs negative)
Mean or n SD or % Mean or n SD or % Mean or n SD or %
Age, years 55.42 12.04 57.16 11.45 54.98 12.16 1.02 (1.00, 1.03) 0.0481
Female, % 833 86.50% 175 90.21% 658 85.57% NS
White, % 816 84.74% 160 82.47% 656 85.31% NS
Disease duration, years 11.04 9.47 11.29 9.55 10.98 9.46 NS
Disease subsets, % NS
Limited disease 563 59.26% 121 62.69% 442 58.39%
Diffuse disease 356 37.47% 69 35.75% 287 37.91%
Sine scleroderma 31 3.26% 3 1.55% 28 3.70%
Modified Rodnan skin score (range, 0-51) 10.02 9.47 9.68 8.53 10.11 9.69 NS
Swollen-joint count
(range, 0-28)
0.91 3.34 1.07 4.26 0.87 3.07 NS
Number of GI symptoms (range 0-14) 4.17 3.13 4.27 3.30 4.14 3.09 NS
Inflammatory myositis, % 103 11.48% 21 11.54% 82 11.47% NS
Thrombosis, % 29 3.06% 7 3.65% 22 2.91% NS
Scleroderma renal crisis, % 42 4.44% 7 3.65% 35 4.64% NS
Interstitial lung disease, % 342 36.19% 85 44.27% 257 34.13% 1.53 (1.11, 2.12) 0.0091
Pulmonary hypertension,% 96 11.72% 26 15.38% 70 10.77% NS
Overlap with SLE, % 30 3.19% 8 4.23% 22 2.93% NS
Overlap with Sjögren, % 63 6.70% 18 9.52% 45 5.98% NS
Overlap with RA, % 30 3.19% 8 4.23% 22 2.93% NS
Overlap with MCTD, % 20 2.13% 7 3.70% 13 1.73% NS
Overlap with PM/DM, % 36 3.83% 12 6.35% 24 3.19% 2.06 (1.01, 4.19) 0.0431
Overlap syndrome, % 143 15.18% 41 21.58% 102 13.56% 1.75 (1.17, 2.63) 0.0059
CI, confidence interval; GI, gastrointestinal; MCTD, mixed connective tissue disease; NS, not significant; overlap syndrome, overlap with systemic lupus
erythematosus, Sjögren syndrome, rheumatoid arthritis, mixed connective tissue disease, and/or polymyositis/dermatomyositis; PM/DM, polymyositis/
dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus.
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Antibodies to Ro52/TRIM21 overlapped with many
other autoantibodies (Table 4). However, the association
between anti-Ro52/TRIM21 antibodies and other auto-
antibodies differed according to antibody. Indeed,
whereas 16% of the overall cohort had anti-topoisome-
rase I antibodies, only 10% of anti-Ro52/TRIM21-posi-
tive patients had anti-topoisomerase I antibodies (P =
0.0129), and the titers of anti-Ro52/TRIM21 antibodies
were among the lowest measured (mean titer, 763.28 U/
ml) in this subset of patients. Conversely, whereas 6% of
the overall cohort had anti-Ro60 antibodies, 21% of
anti-Ro52/TRIM21 antibody-positive patients were anti-
Ro60 positive (P < 0.0001), and the titers of anti-Ro52/
TRIM21 antibodies were among the highest measured
(mean titer, 5,530.66 U/ml). Similarly strong associa-
tions between anti-Ro52/TRIM21 antibodies and anti-
Ro60 were noted between anti-Ro52/TRIM21 and
anti-U1 RNP (P = 0.0066; mean titer, 2,099.45 U/ml),
anti-SS-B/La (P < 0.0001; mean titer, 6,003.88 U/ml),
and anti-Jo-1 (P = 0.0171; mean titer, 4,412.83 U/ml),
and to a lesser degree between anti-Ro52/TRIM21 and
anti-CENP-B (P = 0.0372; mean titer, 1,098.86 U/ml)
and anti-Sm (P = 0.0361; mean titer, 1,482.09 U/ml)
antibodies.
Finally, anti-Ro52/TRIM21 antibody titers were sig-
nificantly higher in patients with compared to patients
without overlap syndrome (mean titer, 1,330.40 versus
1,105.05 U/ml, respectively; P = 0.0026). A strong
trend was noted toward higher titers in patients with
compared to those without interstitial lung disease
(mean titer, 1,542.65 versus 938.11 U/ml, respectively;
P = 0.06).










Odds ratio (95% CI) and P values
(Anti-Ro52/TRIM21 positive vs
negative)
Mean SD Mean SD Mean SD
General 0.89 1.22 1.16 1.41 0.82 1.16 1.23 (1.09, 1.39) 0.0061
Skin 1.25 0.68 1.23 0.60 1.25 0.69 NS
Kidney 0.12 0.61 0.12 0.61 0.12 0.61 NS
Peripheral vascular 1.54 1.25 1.58 1.26 1.53 1.24 NS
Joint/tendon 0.73 1.19 0.73 1.22 0.73 1.18 NS
Muscle 0.25 0.74 0.33 0.89 0.22 0.70 NS
Gastrointestinal 1.95 0.82 2.01 0.78 1.93 0.82 NS
Lung 1.38 1.11 1.56 1.08 1.34 1.12 1.19 (1.04, 1.37) 0.0084
Heart 0.50 1.00 0.60 1.12 0.48 0.97 NS
Physician global assessments of severity (range, 0-10) 2.77 2.26 2.99 2.31 2.71 2.24 NS
Patient global assessments of severity (range, 0-10) 3.64 2.61 3.66 2.67 3.63 2.60 NS
CI, confidence interval; NS, not significant; SD, standard deviation.







P values Mean anti-Ro52/TRIM21 titer
(U/ml)
n % n % n %
Centromere 334 34.76% 78 40.41% 256 33.33% NS 1,098.64
Topoisomerase I 150 15.58% 19 9.79% 131 17.04% 0.0129 763.28
RNApolIII 144 18.58% 23 15.75% 121 19.24% NS 1,164.47
Pm/Scl 53 6.84% 10 6.85% 43 6.84% NS 1,381.13
U1 RNP 59 6.13% 20 10.31% 39 5.07% 0.0066 2,099.45
CENP-B 285 35.58% 64 42.95% 221 33.90% 0.0372 1,098.86
CENP-A 275 34.33% 61 40.94% 214 32.82% NS 1,019.93
Ro60 53 5.50% 40 20.62% 13 1.69% < 0.0001 5,530.66
SS-B/La 26 2.70% 18 9.28% 8 1.04% < 0.0001 6,003.88
Jo-1 6 0.62% 4 2.06% 2 0.26% 0.0171 4,412.83
Sm 39 4.05% 13 6.70% 26 3.38% 0.0361 1,482.09
Ribosomal P 14 1.45% 3 1.55% 11 1.43% NS 2,088.14
Chromatin 44 4.57% 10 5.15% 34 4.42% NS 1,162.30
NS, not significant.
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Discussion
In this large, multicenter cohort study, we found that
anti-Ro52/TRIM21 antibodies were present in 20% of
963 patients, making them the second most common
autoantibodies in this SSc cohort, and they overlapped
with all of the major SSc-related antibodies. In addition,
in this cohort of SSc patients, we found strong sugges-
tions of an association between anti-Ro52/TRIM21 anti-
bodies and interstitial lung disease and overlap
syndrome.
Several studies have demonstrated that anti-Ro52/
TRIM21 antibodies are present in several systemic auto-
immune rheumatic diseases [11,28-31]. In particular,
anti-Ro52 antibodies are frequently found in the inflam-
matory myositides, often in the presence of anti-Jo1 and
interstitial lung disease [32-34].
The largest study to date of anti-Ro52 in SSc (mea-
sured using an ELISA), a recent British report of 1,010
SSc patients, found an overall frequency of anti-Ro52/
TRIM21 antibodies of 27% [35]. We have shown that
the ALBIA anti-Ro52/TRIM21 antibody has high con-
cordance (> 95%) with an anti-Ro52/TRIM21 ELISA
(unpublished data), suggesting that the higher preva-
lence in the British study is not related to interlabora-
tory assay variation. Although the majority of our
patients were White (85%), the British study did not
report on the ethnic profile or disease duration of their
patients. The British study also showed that anti-Ro52/
TRIM21 antibodies overlapped with all of the major
SSc-related antibodies, including anti-centromere, anti-
topoisomerase I, and anti-RNA polymerase III antibo-
dies (in their study, at frequencies of 28%, 19%, and
25%, respectively). In addition, they confirmed that anti-
Ro52/TRIM21 antibody titers were particularly elevated
in patients with anti-Ro60 and anti-aminoacyl-tRNA
synthetase antibodies (of whom four were anti-Jo1 posi-
tive). Although the authors did not present actual clini-
cal data, they nevertheless concluded that Ro52/TRIM21
antibodies appeared to be general serum markers with
limited linkage to distinct clinical manifestations of SSc.
In another recent study by Ghillani et al. [36], 155
patients positive for anti-Ro52/TRIM21 antibodies but
negative for anti-Ro60 antibodies were analyzed. The
authors found that anti-Ro52/TRIM21 antibodies were
commonly found in the presence of other autoantibo-
dies (in particular, Sm, chromatin, Jo-1, and CENP-B)
and that 73% of patients had an autoimmune disease (in
particular, polymyositis/dermatomyositis, SjS, SSc, and
autoimmune hepatitis). Interestingly, the authors
reported that the prevalence of pulmonary disease was
particularly high among anti-Ro52/TRIM21 antibody-
positive patients (22% of patients), including seven of 11
patients with SSc.
A recent article from the German Network for Sys-
temic Sclerosis specifically examined the clinical corre-
lates of a number of autoantibodies in SSc, including
Ro52 [37]. They found that the prevalence anti-Ro52
antibody in their cohort (N = 863) was 21.7% and that
25% of patients with overlap syndrome were positive for
anti-Ro52 antibody. Although they did not find any sta-
tistically significant association between anti-Ro52 anti-
bodies and specific clinical features, it is interesting to
note that their point estimate for an association with
pulmonary fibrosis was 1.3. They also reported a statisti-
cally significant twofold increase in the rate of pulmon-
ary fibrosis among patients who had anti-Ro60
antibodies (odds ratio (OR), 2.20; 95% confidence inter-
val (CI), 1.29 to 3.75; P = 0.004). In our study, the rate
of interstitial lung disease among anti-Ro52/TRIM21
antibody-positive patients was significantly increased by
50% compared with anti-Ro52/TRIM21 antibody-nega-
tive patients (OR, 1.53; 95% CI, 1.11 to 2.12; P =
0.0091). In addition, the association between anti-Ro60
antibody and interstitial lung disease was increased
almost threefold (OR, 2.86; 95% CI, 1.62 to 5.04; P =
0.0002; data not shown).
Thus, the findings of our study are generally consis-
tent with the current literature. In addition to confirm-
ing the serologic associations between anti-Ro52/
TRIM21 antibodies and other autoantibodies, we found
important associations between anti-Ro52/TRIM21 anti-
bodies, interstitial lung disease, and overlap syndrome.
Overlap syndrome is highly prevalent among patients
with systemic autoimmune rheumatic diseases and is
thought to suggest that these diseases share similar
immunogenetic mechanisms [38-40]. The concept of
“overlap” syndrome in SSc, however, remains elusive,
with some of the common manifestations of the disease,
including sicca and myositis, being possibly related to
SSc itself or to a separate autoimmune disease. We
believe that serologic associations could help to shape a
better definition of overlap in SSc, and that anti-Ro52/
TRIM21 antibodies have the potential to be good bio-
markers of overlap in this disease.
The Ro52 gene has been mapped to the end of the
short arm of human chromosome 11 [29]. Evidence sug-
gests that this chromosome segment may harbor genes
important in the development and progression of solid
tumors. Given this, we reviewed our data and found
that 12.04% of anti-Ro52/TRIM21 antibody-positive
patients compared with 7.24% of anti-Ro52/TRIM21
antibody-negative patients had a physician-reported his-
tory of malignancy (P = 0.03). These data have yet to be
validated through chart review and remain preliminary.
Our understanding of how a number of SSc-related
autoantibodies are generated (for example, through
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apoptosis, microbody release, molecular mimicry, or
other mechanisms) and of their role in the pathogenesis
of disease has increased remarkably over the past two
decades (reviewed in [41,42]). The recently reported
mechanism of intracellular immunity mediated by Ro52/
TRIM21 in a cellular model of adenovirus infection has
opened new perspectives for studying the effects of
autoantibodies once they are inside cells [10]. The asso-
ciation between Ro52/TRIM21 and other proteins such
as TRIB2, implicated in driving tumorigenesis [43], with
Fas-associated death domain (FADD) and negatively reg-
ulating the IFN-a pathway in response to viral infection
[44] and its interaction with virus-like particles and
high-affinity IgG receptors affecting the intracellular fate
of viruses, including degradation by the proteasomes
[10,45,46] may provide important insights into the gen-
eration of the autoantibody response and its perpetua-
tion in SSc. Further, the association of anti-Ro52/
TRIM21 antibodies with cytokine responses such as
IFN-a [44] and Toll-like receptor-mediated NF-B acti-
vation [47] provides some insight into its regulation of
cytokine responses. Thus, despite clearer understanding
of the physiological function of Ro52/TRIM21 in vitro,
it is still unclear how anti-Ro52/TRIM21 antibodies
arise, particularly in vivo, and whether they have any
pathologic significance in SSc or other systemic autoim-
mune rheumatic diseases. Of note, though, is the fact
that anti-Ro52/TRIM21 antibodies are seen across a
number of autoimmune diseases with significant preva-
lence (ranging from 1% to 63%) but are only rarely seen
in normal controls; this suggests that they are markers
of autoimmune dysfunction [29]. Further studies will be
needed to shed greater insight into their precise role in
autoimmune diseases.
Conclusions
We believe that this study makes a significant contribu-
tion to the literature on the clinical significance of anti-
Ro52/TRIM21 antibodies. Although consistent data
show that SSc-specific antibodies are generally mutually
exclusive, it is important to appreciate that a multiplicity
of other nonspecific markers of humoral immune
response exist in SSc, with Ro52/TRIM21 being one of
the most common of these. In addition, Ro52/TRIM21
appears to have distinct clinical associations in SSc, in
particular with interstitial lung disease and overlap syn-
drome. These data suggest that Ro52/TRIM21 may be
of both diagnostic and prognostic importance in SSc.
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